Related Experiment Video
Updated: Aug 7, 2026
06:02
Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses
Published on: February 23, 2024
Regulatory considerations on new adjuvants and delivery systems
1National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK. dsesardic@nibsc.ac.uk
Vaccine
|July 11, 2006
Summary
New vaccine adjuvants and delivery systems require rigorous pre-clinical evaluation. Current regulatory guidelines for vaccine safety assessment are insufficient, necessitating case-by-case toxicological studies.
Area of Science:
- Vaccinology
- Toxicology
- Regulatory Science
Background:
- New vaccines and delivery systems are crucial for human disease prevention and treatment.
- Pre-clinical evaluation is essential for establishing biological properties, assessing public risk, and planning clinical trials.
- Vaccine pre-clinical studies inform optimal composition, formulation, and quality control tests.
Purpose of the Study:
- To highlight the importance of pre-clinical evaluation for novel vaccines and delivery systems.
- To address the challenges posed by new adjuvants and delivery systems for manufacturers and regulators.
- To emphasize the need for case-by-case toxicological assessments for adjuvants and adjuvant/vaccine combinations.
Main Methods:
- Review of current pre-clinical evaluation practices for vaccines.
- Analysis of regulatory requirements for vaccine safety assessment.
- Discussion of challenges in evaluating new adjuvants and delivery systems.
Main Results:
- Pre-clinical studies are vital for vaccine development, quality control, and regulatory approval.
- New adjuvants require specific safety evaluations due to their unique regulatory status.
- Existing regulatory guidelines for vaccine safety assessment are inadequate for novel components.
Conclusions:
- Enhanced pre-clinical and toxicological studies are needed for new vaccine adjuvants and delivery systems.
- Regulatory frameworks must evolve to address the complexities of modern vaccine development.
- Developing specific guidelines for adjuvant evaluation is critical for ensuring vaccine safety and efficacy.
More Related Videos
Related Concept Videos
01:20Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:26Antigens Involved in Adaptive Immunity
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...